Bluejay Diagnostics stock gained 6.50 percent as SYMON-II data emerged
Published on 10/08/2026 at 03:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bluejay Diagnostics stock (ISIN US0956336087) closed at USD 0.8107 on Nasdaq on October 6, 2026, up 6.50 percent from the prior close. The move followed preliminary SYMON-II clinical data covering 777 patients, according to Morningstar on October 6, 2026.
SYMON-II reaches 777 patients
The preliminary analysis included 637 patients who survived 28 days and 140 who did not, producing 18 percent overall mortality in the study population. The dataset was designed to evaluate interleukin-6, or IL-6, as a biomarker associated with mortality risk in sepsis and septic shock.
StockTitan reported that Bluejay Diagnostics shares closed 6.50 percent higher in the October 6 session as the clinical dataset reached the market. The same report placed the preliminary study population at 39.5 percent meeting Sepsis-3 criteria for septic shock.
Mortality gap frames the data
Septic shock was present in 56.4 percent of the non-survivor group, compared with 35.8 percent of survivors, a 20.6 percentage-point difference. Bacterial infection was reported in 84.0 percent of patients, while positive blood cultures occurred in 32.4 percent.
Those figures establish the clinical severity of the sample, but they do not establish the Symphony IL-6 Test's prognostic performance, sensitivity, specificity or regulatory acceptability. Bluejay said the analysis of IL-6 measurements and their relationship with mortality and other clinical parameters is continuing.
FDA clearance remains pivotal
Bluejay is developing the Symphony Suite as a rapid near-patient testing platform for sepsis triage and monitoring. The company plans to use SYMON-II to support a 510(k) application, while the Symphony IL-6 Test remains investigational and requires FDA clearance before commercial use in the United States.
For investors, the dataset therefore supplies a larger clinical base rather than a commercial revenue milestone. The next valuation step depends on the completed biomarker analysis and the regulatory path that follows it.
Bluejay Diagnostics stock closed at USD 0.8107
Bluejay Diagnostics stock closed at USD 0.8107 on Nasdaq on October 6, 2026, with a 52-week range of USD 0.76 to USD 16.68 and market capitalization of USD 0.8 million as of October 7, 2026.
Bluejay Diagnostics stock facts
- Company: Bluejay Diagnostics, Inc.
- ISIN: US0956336087
- Ticker: BJDX
- Trading venue: Nasdaq
- Price (as of October 6, 2026, 4:00 p.m. EDT): Closing price (October 6, 2026) USD 0.8107
- Market capitalization: USD 0.8 million (as of October 7, 2026)
- 52-week range: USD 0.76-16.68 (as of October 7, 2026)
- Sector / Industry: Healthcare / Medical Devices
